MedPath

Ombitasvir/Paritaprevir/Ritonavir

Generic Name
Ombitasvir/Paritaprevir/Ritonavir
Indication

用于治疗成人基因1型慢性丙型肝炎，包括无肝硬化或伴代偿期肝硬化的患者。该治疗方案是全口服的、无干扰素、可联合或不联合利巴韦林。

Clinical Trials
Related News

eGFR Evolution in HCV Patients Receiving SOF-based or SOF-free DAAs

First Posted Date
2019-08-07
Last Posted Date
2019-08-08
Lead Sponsor
National Taiwan University Hospital
Target Recruit Count
441
Registration Number
NCT04047680
Locations
🇨🇳

National Taiwan University Hospital, Yun-Lin Branch, Douliu, Taiwan

🇨🇳

National Taiwan University Hospital, Taipei, Taiwan

Comparative Study of Two Regiemns in Management of Sofosbuvir/Daclatasvir Failure

First Posted Date
2018-06-08
Last Posted Date
2019-03-19
Lead Sponsor
Assiut University
Target Recruit Count
40
Registration Number
NCT03549832
Locations
🇪🇬

Assiut University Hopsital, Assiut, Egypt

Effect Of DAAs For Treatment Of HCV On Normal Kidney

Phase 4
Conditions
Antiviral Drug Adverse Reaction
Interventions
First Posted Date
2017-09-29
Last Posted Date
2017-09-29
Lead Sponsor
Assiut University
Target Recruit Count
100
Registration Number
NCT03296930

Effectiveness, Safety and Clinical Outcomes of Paritaprevir/Ombitasvir/r+Dasabuvir 8 Weeks

Completed
Conditions
Hepatitis C Infection
Interventions
First Posted Date
2017-04-20
Last Posted Date
2018-05-21
Lead Sponsor
Hepa C
Target Recruit Count
200
Registration Number
NCT03122132
Locations
🇪🇸

Carrion, Jose Antonio, PhD, Barcelona, Spain

Study of Ombitasvir/Paritaprevir/Ritonavir in Japanese Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection With End Stage Renal Disease (ESRD) on Hemodialysis (HD)

Phase 3
Withdrawn
Conditions
Chronic Hepatitis C Virus
Interventions
First Posted Date
2016-06-20
Last Posted Date
2016-12-05
Lead Sponsor
AbbVie
Registration Number
NCT02806362

Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin and Patient Support Program in Patients With Chronic Hepatitis C

Completed
Conditions
Chronic Hepatitis C
Interventions
Behavioral: Patient support program
First Posted Date
2016-06-16
Last Posted Date
2019-10-11
Lead Sponsor
AbbVie
Target Recruit Count
256
Registration Number
NCT02803138
Locations
🇮🇱

Ha'Emek Medical Center /ID# 153695, Afula, Israel

🇮🇱

Assaf Harofeh Medical Center /ID# 153708, Be'er Ya'akov, Israel

🇮🇱

The Edith Wolfson Medical Cent /ID# 153706, Holon, Israel

and more 15 locations

A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Chronic Hepatitis C Virus Infection

Phase 3
Completed
Conditions
Chronic Hepatitis C Virus
Hepatitis C Virus
Interventions
First Posted Date
2016-03-14
Last Posted Date
2021-07-16
Lead Sponsor
AbbVie
Target Recruit Count
295
Registration Number
NCT02707952

Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Low-Dose Ribavirin QD in Subjects With Genotype 1a Chronic Hepatitis C Virus Infection

Phase 3
Completed
Conditions
Hepatitis C Virus (HCV)
Interventions
First Posted Date
2015-11-20
Last Posted Date
2019-12-10
Lead Sponsor
AbbVie
Target Recruit Count
105
Registration Number
NCT02609659

The Effectiveness of ABT-450/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C -An Observational Study in Ireland

Completed
Conditions
Chronic Hepatitis C
Interventions
First Posted Date
2015-10-21
Last Posted Date
2019-05-06
Lead Sponsor
AbbVie
Target Recruit Count
101
Registration Number
NCT02582671

A Study to Evaluate Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve Hepatitis C Virus Genotype 1b-Infected Adults

Phase 3
Completed
Conditions
Hepatitis C Infection
Hepatitis C Virus
Interventions
First Posted Date
2015-10-21
Last Posted Date
2021-07-30
Lead Sponsor
AbbVie
Target Recruit Count
166
Registration Number
NCT02582632
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy